Nxera Pharma Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Nxera’s participation in OpenFold is aligned with the Company’s policy to enhance R&D productivity and business efficiency through the use of AI technologies, as presented at the Company’s 36th Ordinary General Meeting of Shareholders held on 25 March 2026.